Financing channel feed – Endpoints News

Financing channel feed

Hong Kong IPO delivers $421M to Innovent as another one of China's biotech unicorns hauls in big money

7 years ago

Bain’s Adam Koppel commits $350M to launching a new biotech that is carving out Pfizer’s neuro pipeline

7 years ago

In key endorsement, Deerfield reserves $65M for drug venture with UNC-Chapel Hill

7 years ago

Medicines Co execs grab a $33M A round to spin out an infectious disease outfit with a pipeline

7 years ago

Fidelity, Valor pool $71.8M for Jeff Aronin's plan to reformulate a generic for butterfly skin disease at Castle Creek Pharma

7 years ago

TP Therapeutics grabs $80M mezzanine round to fund a pivotal trial for ROS-1/NTRK-positive cancers

7 years ago

Biotech vets launch a neuro startup with $54.5M to kickstart R&D

7 years ago

Six years after a spectacular debut, Warp Drive Bio is powering down and handing its 'undruggable' ambitions over to Revolution

7 years ago

Taiho antes up an extra $250M for its venture arm as it gets serious about 'global oncology' deals

7 years ago

Innovent to seek $400M-plus on Hong Kong IPO, reports say; will it revive biotech's fortunes on HKEX?

7 years ago

Arie Belldegrun and David Chang score record IPO, now they plan to win the race to a historic FDA OK

7 years ago

Versant-backed Gotham Therapeutics launches with $54M round and a new way to connect on mRNA

7 years ago

MIT spinout from Sangeeta Bhatia’s lab gets a $22M round to develop new disease and drug sensors

7 years ago

5AM partners set a wakeup call for biotech Fund VI, shooting for a record $350M

7 years ago

GSK hands cash and tech to a biotech startup pointed down the same R&D road they want to travel

7 years ago

From mega-round to $172M IPO in weeks, Orchard is bundling cash to back its play on GSK's gene therapy cast-offs

7 years ago

Blackstone bags Clarus, staking out a growing PhIII niche for itself in a rapidly changing biopharma industry

7 years ago

Belldegrun and Chang groom their biotech unicorn Allogene for a monster $288M — or so — IPO

7 years ago

F-Prime's Ben Auspitz co-leads $30M Series A with OrbiMed for his latest rare disease venture

7 years ago

Nasdaq wraps up Q3 with IPO pitches from Gamida Cell, NGM, Arog totalling $219M

7 years ago

Three years after selling Acerta to AstraZeneca in $7B deal, Dave Johnson is back at the helm of a biotech startup

7 years ago

Gritstone’s top-of-the-range IPO brings week’s biotech Nasdaq tally to $520M

7 years ago

Fast-growing KSQ and David Meeker fuel up with a hefty $80M round on the way to first human studies

7 years ago

New York cancer center launches 'historic' JV to bring Cuban-developed cancer drugs to US

7 years ago

First page Previous page 120 121 122123124 125 126 Next page Last page